https://antliabio.com/. Turning promising peptides into groundbreaking therapeutics for chronic diseases. Co-Founder & Chief Executive Officer at Antlia Bioscience, Inc.. University of the Pacific - McGeorge School of Law. Started my biotech in April 2020, closed a seed round that year, and I am in the process of working through a much larger capital raise (another Seed Round, followed by a priced Series A later this year to fund my first in-human clinical trial). 619-990-0290. Antlia Bioscience is a San Diego-based biotech developing groundbreaking peptide-based therapies to treat cardiovascular and pulmonary diseases. We use PASylation® a proprietary and powerful chemistry platform to design novel long-acting peptides with fine-tuned pharmacologic and pharmacokinetic properties to create promising therapeutics for chronic diseases. . 2/16/22 - Brian + Twos Guys. Looking for a 26-30 million series A. 60M pre-money. 5% in seed for $2 million